Vincenzo Malagnino, Tiziana Mulas, Elisabetta Teti, Monica Basso, Mario Giobbia, Nicholas Geremia, Giuliana Battagin, Yasmine Abi Aad, Jean-Paul Vincensini, Marco Iannetta, Saverio Giuseppe Parisi, Loredana Sarmati, Karine Lacombe
Hepatitis B Core antibody (HBcAb) positivity is the surrogate marker of hepatitis B occult infection. This condition is not a contraindication for switching to two-drug (2DR) antiretroviral therapy; however, the removal of tenofovir may contribute to poor control of HBV replication. A multicentre retrospective cohort study investigated the impact of HBcAb positivity on HIV control in patients switching to a 2DR with Lamivudine and Dolutegravir (3TC-DTG). In this study, a comparison analysis was conducted between HBcAb-positive and -negative PLWH regarding HIV-RNA suppression, considering: (1): Target Not Detected (TND) < 20 cp/mL; (2) Target Detected (TD) < 20 cp/mL; and (3) Detectable > 20 cp/mL and <50 cp/mL and >50 copies/mL...
February 23, 2024: Viruses